News | Nuclear Imaging | December 14, 2020

The Journal of Nuclear Medicine Celebrates 60 Years of Research

JNM celebrates 60 years of nuclear medicine research. Image courtesy of Society of Nuclear Medicine and Molecular Imaging.

December 14, 2020 — The Journal of Nuclear Medicine (JNM) has issued a special supplement commemorating six decades of leadership in the field of nuclear medicine, molecular imaging and therapy.

The supplement features a collection of the most influential and frequently cited manuscripts in JNM's history, representing seminal discoveries and scientific contributions that shaped the future of medicine. Invited perspectives from world leaders in nuclear medicine, molecular imaging, and theranostics explain why each of these articles had such an enormous impact.

Highlights include milestone articles on the invention of the Anger camera, the creation of positron emission tomography (PET) and 18F-FDG, the development of fusion PET/CT, the introduction of FDG PET-based response criteria in solid tumors, and many more landmark papers that have shaped the history of nuclear medicine.

Moving from the past to the present and beyond, the special issue concludes with the JNM associate editors' views on the most promising future applications of nuclear medicine. "We hope to demonstrate that the field not only is highly relevant for diagnosing and understanding the pathophysiology of human diseases but also is increasingly becoming an integral part of patient management," they said.

"Our collective success is rooted in the research that scientists from around the globe submit to JNM, the tireless efforts of reviewers and editorial board members, and the commitment and interest of readers," said JNM Editor-in-Chief Johannes Czernin, M.D. "Substantial credit for the success of JNM also goes to its past editors, who each made unique contributions to establish JNM as the world's leading journal on nuclear medicine and molecular imaging."

For more information: www.snmmi.org

Related Content

After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by

After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by N. Galldiks et al., Research Center Juelich, Juelich, Germany.

News | PET Imaging | May 05, 2021
May 5, 2021 — For patients with brain metastases, amino acid ...
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Getty Images

Feature | Radiation Oncology | May 04, 2021 | By Vinay Shivaprasad
The term nuclear medicine is associated with the diag
olecular Targeting Technologies, Inc. (MTTI) announced the issuance of United States Patent # 10,953,113. The patent claims a quick (5 min), easy and quantitative conversion of commercially available 18F-deoxyglucose (18F-FDG) to 18F-Fluroglucaric acid (18F-FGA).

Getty Images

News | PET Imaging | April 19, 2021
April 19, 2021 — Molecular Targeting Technologies, Inc.
The inflamed joints of a #rheumatoid #arthritis patient are clearly visible in the #PET images with the novel 68Ga-DOTA-Siglec-9 #radiopharmaceutical. Image courtesy of Anne Roivainen

The inflamed joints of a rheumatoid arthritis patient are clearly visible in the PET images with the novel 68Ga-DOTA-Siglec-9 radiopharmaceutical. Image courtesy of Anne Roivainen

News | PET Imaging | April 19, 2021
April 19, 2021 — The preliminary...
#NorthStar Medical #Radioisotopes, LLC, a global innovator in the development, production and commercialization of #radiopharmaceuticals used for #medicalimaging and #therapeutic applications, announced a corporate update highlighting progress across its key programs during the past twelve months and upcoming milestones.

NorthStar Medical Radioisotopes, Beloit, Wisconsin campus (Photo: Business Wire)

News | Radiopharmaceuticals and Tracers | April 16, 2021
April 16, 2021 — ...

Scan of brain of someone who did not develop TTS. Image courtesy of European Heart Journal

News | PET-CT | March 29, 2021
March 29, 2021 — Heightened activity in the brain, caused by stressful events, is linked to the risk of developing a
Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status

Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status. Image courtesy of Shine Medical Technologies

News | Radiopharmaceuticals and Tracers | March 26, 2021
March 26, 2021 — Shine Medical Technologies LLC announced that construction of the exterior structure of its first-of